A Study of Immune System Activity in Healthy Adults
A Study of Immune Function in Healthy Adults Aged 18-30 and 45 and Older
2 other identifiers
observational
48
1 country
9
Brief Summary
The purpose of this study is to compare immune system activity in young people and older people who do not have HIV. This information will be compared to that of HIV patients in another study. Aging affects immune system activity. This study will look at some of the factors involved. HIV also affects immune system activity. The results from this study, using healthy volunteers, will be compared to those in another study of HIV-infected patients. This may provide information on immune system activity in aging and HIV.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2001
CompletedFirst Posted
Study publicly available on registry
August 31, 2001
CompletedJuly 30, 2008
June 1, 2003
April 10, 2001
July 29, 2008
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- Volunteers may be eligible for this study if they:
- Are willing to undergo HIV testing.
- Have a negative urine or serum pregnancy test within 30 days prior to study entry (for women volunteers).
- Are between the ages of 18 and 30 or are 45 or older.
You may not qualify if:
- Volunteers will not be eligible for this study if they:
- Have HIV infection.
- Have a serious infection or other serious medical illness that requires treatment and/or hospitalization within 90 days before study entry.
- Have had cancer.
- Have received any of the following within 6 months of study entry: systemic corticosteroids; chemotherapy or radiation; erythropoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or growth hormone; drugs that affect the immune system including thalidomide, interleukins, interferons, or other cytokines; anabolic steroids at high levels; or any experimental agent, unless allowed otherwise by the researchers.
- Are immune to hepatitis A.
- Have received tetanus toxoid within 5 years prior to study entry or have a history of severe reaction to tetanus vaccine at any time in the past.
- Are pregnant or breast-feeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Univ of California San Francisco
San Francisco, California, 94110, United States
Univ of Colorado Health Sciences Ctr
Denver, Colorado, 80262, United States
Univ of Hawaii
Honolulu, Hawaii, 96816, United States
Northwestern Univ Med School
Chicago, Illinois, 60611, United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612, United States
Washington Univ School of Medicine
St Louis, Missouri, 63108, United States
Case Western Reserve Univ
Cleveland, Ohio, 44106, United States
Univ of Texas Galveston
Galveston, Texas, 775550435, United States
Univ of Washington
Seattle, Washington, 98104, United States
Related Publications (1)
Tenorio AR, Spritzler J, Martinson J, Gichinga CN, Pollard RB, Lederman MM, Kalayjian RC, Landay AL. The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol. 2009 Mar;130(3):298-303. doi: 10.1016/j.clim.2008.10.001. Epub 2008 Nov 12.
PMID: 19008157DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Robert Kalayjian
Study Design
- Study Type
- observational
- Sponsor Type
- NIH
Study Record Dates
First Submitted
April 10, 2001
First Posted
August 31, 2001
Last Updated
July 30, 2008
Record last verified: 2003-06